ADVFN Logo ADVFN

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.678,74
-0,74%
S&P 500
5.693,31
-0,33%
Dow Jones
42.299,70
-0,37%
Euro vs US Dollar
1,07889
-0,11%
Bitcoin
86.677,63
-0,61%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) News

BBIO

BridgeBio Pharma (BBIO)

BridgeBio Pharma Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BBIO
DatumZeitQuelleÜberschriftSymbolFirma
27/03/202512h00GlobeNewswire Inc.Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CMNASDAQ:BBIOBridgeBio Pharma Inc
24/03/202512h30GlobeNewswire Inc.BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific SessionsNASDAQ:BBIOBridgeBio Pharma Inc
21/03/202523h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
21/03/202523h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
21/03/202521h00GlobeNewswire Inc.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BBIOBridgeBio Pharma Inc
17/03/202521h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
17/03/202521h01GlobeNewswire Inc.BridgeBio Announces CFO SuccessionNASDAQ:BBIOBridgeBio Pharma Inc
10/03/202521h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
08/03/202500h15Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:BBIOBridgeBio Pharma Inc
06/03/202522h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
06/03/202503h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
28/02/202522h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
28/02/202502h22Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
26/02/202508h49GlobeNewswire Inc.BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured DebtNASDAQ:BBIOBridgeBio Pharma Inc
25/02/202522h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
24/02/202522h09GlobeNewswire Inc.BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured DebtNASDAQ:BBIOBridgeBio Pharma Inc
20/02/202522h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BBIOBridgeBio Pharma Inc
20/02/202513h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
20/02/202513h30GlobeNewswire Inc.BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial UpdateNASDAQ:BBIOBridgeBio Pharma Inc
20/02/202502h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
20/02/202502h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
19/02/202522h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
13/02/202522h01GlobeNewswire Inc.BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025NASDAQ:BBIOBridgeBio Pharma Inc
11/02/202515h21GlobeNewswire Inc.BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CMNASDAQ:BBIOBridgeBio Pharma Inc
31/01/202500h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
28/01/202522h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BBIOBridgeBio Pharma Inc
13/01/202522h53Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BBIOBridgeBio Pharma Inc
13/01/202517h00GlobeNewswire Inc.BridgeBio Announces Commercial Progress, Program Updates, and 2025 MilestonesNASDAQ:BBIOBridgeBio Pharma Inc
08/01/202513h30GlobeNewswire Inc.BridgeBio Pharma to Participate in the J.P. Morgan Healthcare ConferenceNASDAQ:BBIOBridgeBio Pharma Inc
13/12/202413h18GlobeNewswire Inc.Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)NASDAQ:BBIOBridgeBio Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:BBIO

Kürzlich von Ihnen besucht

NASDAQ
CEBKX
Ci Global Longevity Econ...
NASDAQ
CCWVX
Ci Doubleline Total Retu...
Delayed Upgrade Clock
ADVFN Logo
Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten